EUVIMEDOpdag EUVIMED
Crossref

Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections

Katie B Olney iD, Manjunath P Pai iD, Jenni K Thomas iD, Donna R Burgess, William J Olney iD, Rebecca A Bruning iD, Kamron A Griffith, Danielle V Casaus, Elizabeth Crance, James Z Porterfield, David S Burgess iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.4602 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Written by Katie B Olney and 10 co-authors. Institution: Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky, USA. Major MEDLINE topics: Daptomycin, Anti-Bacterial Agents, Staphylococcal Infections. Cited 15 times so far (Crossref); 24 references. Funded by: Society of Infectious Diseases Pharmacists (SIDP).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Daptomycin is a high‐use intravenous antimicrobial agent affording the convenience of once‐daily dosing. Prior studies suggest an opportunity to use a more operationally convenient fixed rather than weight‐based dosing but this approach has not been studied prospectively.

Methods

This study quantified the probability of toxicity and efficacy end points by prospectively testing a fixed dose regimen of daptomycin (750 mg) in obese and non‐obese adults. At least, three daptomycin concentrations were measured at steady‐state for each patient. A population pharmacokinetic model was constructed to evaluate concentration‐time profiles and investigate covariates of daptomycin clearance. Simulations were performed to evaluate the probability of achieving efficacy (24‐h area under the curve (AUC 0‐24 ) ≥ 666 mg∙h/L) and toxicity (minimum concentration ( C min ) ≥24.3 mg/L) targets for fixed (500–1000 mg) and weight‐based (6–12 mg/kg) daptomycin doses.

Results

Thirty‐one patients (16 females, 15 males) with median (interquartile range (IQR)) age of 50 (30, 62) years and weight of 74 (54, 156) kg were included in the final analysis. Fixed dose daptomycin (750 mg) resulted in similar exposure across weights with a median (IQR) AUC 0‐24 of 819 (499, 1501) mg∙h/L and 749 (606, 1265) mg∙h/L in patients weighing ≤74 kg and >74 kg, respectively. Overall, male sex and increased kidney function necessitate higher fixed and weight‐based doses to achieve efficacy. Creatine phosphokinase elevation was observed in two patients (6.5%) and predicted to be lower with fixed versus weight‐based regimens.

Conclusions

Fixed daptomycin dosing adjusted for sex and kidney function is expected to improve the efficacy‐to‐toxicity ratio, transitions of care, and costs compared to weight‐based doses. However, no empiric dosing approach is predicted to achieve ≥90% efficacy while minimizing the risk of toxicity, so therapeutic drug monitoring should be considered on a patient‐specific basis.

Subjects

MeSH terms (MEDLINE)

DaptomycinAnti-Bacterial AgentsStaphylococcal InfectionsHumansMaleFemaleMiddle AgedAdultProspective StudiesArea Under CurveDose-Response Relationship, DrugModels, BiologicalObesityStaphylococcus aureusBody WeightMicrobial Sensitivity Tests

Author keywords

daptomycinfixed dosepharmacodynamicspharmacokinetics

Substances

DaptomycinAnti-Bacterial Agents

Authors and institutions

  • Department of Pharmacy, University of Kentucky HealthCare, Lexington, Kentucky, USA.
  • Department of Pharmacy Practice and Science, The University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
  • Division of Infectious Diseases, University of Kentucky HealthCare, Lexington, Kentucky, USA.
  • University of KwaZulu-Natal School of Clinical Medicine, Durban, South Africa.

ORCID profiles: Katie B Olney, Manjunath P Pai, Jenni K Thomas, William J Olney, Rebecca A Bruning, David S Burgess

Funding

  • Society of Infectious Diseases Pharmacists (SIDP)

Cite

APA

Olney, K. B., Pai, M. P., Thomas, J. K., Burgess, D. R., Olney, W. J., Bruning, R. A., Griffith, K. A., Casaus, D. V., Crance, E., Porterfield, J. Z., & Burgess, D. S. (2024). Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4602

Vancouver

Olney KB, Pai MP, Thomas JK, Burgess DR, Olney WJ, Bruning RA, et al. Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4602

BibTeX
@article{Olney2024,
  author = {Olney, Katie B and Pai, Manjunath P and Thomas, Jenni K and Burgess, Donna R and Olney, William J and Bruning, Rebecca A and Griffith, Kamron A and Casaus, Danielle V and Crance, Elizabeth and Porterfield, James Z and Burgess, David S},
  title = {Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.4602}
}
Start for free →